S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

2011 ◽  
Author(s):  
L Gianni ◽  
G Romieu ◽  
M Lichinitser ◽  
S Serrano ◽  
M Mansutti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Her2 Positive ◽  
Phase Iii Trial ◽  
First Line Therapy ◽  
Line Therapy ◽  
First Results ◽  
Locally Recurrent

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA1002-CRA1002 ◽  
Author(s):  
Hope S. Rugo ◽  
William Thomas Barry ◽  
Alvaro Moreno-Aspitia ◽  
Alan P. Lyss ◽  
Constance Cirrincione ◽  
...  
Keyword(s):  
Metastatic Breast ◽  
Phase Iii ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent ◽  
Final Text

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document